Florham Park, NJ, May 5, 2021

Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Darifenacin Extended Release Tablets, generic to Enablex®.

 “Xiromed is focused on providing quality generic products to patients in the US and the launch of Darifenacin ER Tablets is the latest example of our commitment to that goal,” commented Xiromed CEO, Narasimhan Mani.

Enablex® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.  Annual market sales for Enablex® ER Tablets and its generics for the twelve month period ending February, 2021 were $11.2 million, according to IQVIA™.     Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.  Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market.  In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products.  Learn more at http://www.xiromed.com/usa/